Welcome
Support Centre
22 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomised, controlled, single blind pilot study to evaluate the efficacy of a mindfulness stress reduction intervention as an adjunct therapy in moderate to severe psoriasis.
ISRCTN ISRCTN51850035
ClinicalTrials.gov identifier
Public title A randomised, controlled, single blind pilot study to evaluate the efficacy of a mindfulness stress reduction intervention as an adjunct therapy in moderate to severe psoriasis.
Scientific title
Acronym N/A
Serial number at source N0013137386
Study hypothesis A randomised, controlled, single blind pilot study to evaluate the efficacy of a mindfulness stress reduction intervention as an adjunct therapy in moderate to severe psoriasis.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised single blind controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Psoriasis
Participants - inclusion criteria Approx 50 adult psoriasis patients attending St John's Institute of Dermatology as an out-patient who have had the diagnosis of psoriasis for at least one year.
Participants - exclusion criteria Does not meet inclusion criteria
Anticipated start date 01/12/2003
Anticipated end date 01/07/2004
Status of trial Completed
Patient information material
Target number of participants 50
Interventions Patients with moderate to severe psoriasis will be randomly assigned at a ratio of 1:1 to receive a mindfulness stress reduction audio tape or nothing (control) as an adjunct treatment to their conventional psoriasis treatment plan. The experimental group subjects will be required to listen to the tape and practice the relaxation technique 3 times a week for 8 weeks. Both groups will be seen at week 0, 4 and 8 for psoriasis severity scores, and psychological assessment scores to evaluate effect.
Primary outcome measure(s) 1. Psoriasis severity measured using the Psoriasis Severity Index (PASI)
2. Mental health using Hospital Anxiety and Depression Scale (HADS)
3. Mental health using Penn State Worry Questionnaire (PSWQ)
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Guy's and St Thomas' NHS Trust (UK)
Trial website
Publications
Contact name Ms  Penelope  Shirlaw
  Address Oral Medicine Department
22nd Floor, Guy's Tower
Guy's Hospital
St Thomas Street
  City/town London
  Zip/Postcode SE1 9RT
  Country United Kingdom
  Tel +44 (0)20 7188 4399
  Email pepe.shirlaw@gstt.sthames.nhs.uk
Sponsor Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
  Address The Department of Health,
Richmond House,
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2004
Last edited 23/09/2009
Date ISRCTN assigned 30/09/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central